Drugs / CMLVAX100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00466726 | Mar 2007 → Jul 2014 | leukemia | GIMEMA Foundation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMLVAX100 | “bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine (CMLVAX100)” NCT00466726 ↗ |
| Modality | Vaccine | “bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine” NCT00466726 ↗ |
| Route | Subcutaneous | “bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine (CMLVAX100) SC on day 2” NCT00466726 ↗ |